

Molecular Diagnosis Of *Aspergillus* Spp. From The Respiratory Tract In Critically Ill Patients In Adewaniyah City.

Laila Jasim Shaebth¹, Nawres Adnan Abdulameer², Thuraya Aamer Habeeb³

^{1,2,3}Technical Institute of Al-Diwaniyah, Al-Furat Al-Awsat Technical University (ATU), Iraq.

Email: laila84@atu.edu.iq, Email: dw.noras@atu.edu.iq, Email: dw.thr@atu.edu.iq

Abstract

Molecular diagnosis for aspergillosis is less monitored due to the poor culture yield of *Aspergillus* spp. To estimate better this shortcoming, the *Aspergillus* spp. was detected and confirmed through respiratory samples from critically ill patients of Adewaniyah city at the high risk of Aspergillosis. The study aimed to notice risk factors, clinical features, management, and outcomes in critically ill patients. PCR technology was used for the diagnosis of invasive Aspergillosis. For this purpose, initially, Magna pure LC instrument was used for automated extraction of fungal DNA of *Aspergillus fumigatus* and *Aspergillus niger*. Assay took 5-6 hours to perform. Oligonucleotide probes and primers were derived from the DNA sequence of 18S rRNA genes of varieties of fungal pathogens for species detection and identification. The database was used to assess fungal infection of *Aspergillus fumigatus* and *Aspergillus niger* from samples of respiratory secretions of 100 (50% male, 50% female, between age 40-50) critically ill patients admitted in ICU. PCR assay gave high sensitivity and specificity for detection and identification of *Aspergillus* spp. from the fluid of respiratory tract of critically ill patients in the hospital ICU.

Introduction:

Aspergillus is the variety of mitosporic parasites and different types of this class are well known for causing contamination. There are some most well known parasites which have the most impacts on general wellbeing where the most noteworthy rate is of *Aspergillus fumigatus* which is 85% while later most renowned is *Aspergillus niger* (Denning 2000). *Aspergillus* spp. is a vital component in causing sickness and aspergillosis in people living in various conditions and confronting distinctive climatic varieties. Mortality in immunosuppressed patients is observed through aspergillosis which was conceded in emergency clinics ICU and was experiencing distinctive other indicative diseases (Humphreys et al. 1991). Immunocompetent patients in ICU can likewise have local area obtained pneumonia because of *Aspergillus* spp. in those individuals which are sufficiently solid (Chen et al.

2001). It is undeniably challenging to analyze aspergillosis until we know about the past clinical history of patients. It additionally needs similarity of *Aspergillus* spp. in the examples by different significant strategies. DNA confirmation is done to affirm the presence of *Aspergillus* spp. which causes aspergillosis in patients. The patients experiencing aspergillosis likewise have the most noteworthy danger of mortality in ordinary and with regards to treatment also. It was introduced the standard meaning of disease through the hematopoietic foundational microorganism treatment in immunosuppressed patients experiencing malignant growth (Ascioglu et al. 2003). Radiological and clinical discoveries affirm the presence of Aspergillosis. While serology isn't substantial for aspergillosis determination and location, and it is restricted in patients experiencing neutropenia (Denning 1998). Treatment of patients is extremely pivotal for the people who are experiencing aspergillosis with neutropenia in immunosuppressed patients and furthermore for patients who are taking immunosuppressant and *Aspergillus* spp. disengagement affirmed aspergillosis. It is undeniably challenging to treat patients experiencing aspergillosis in the respiratory parcel without neutropenia and transplantation while *Aspergillus* spp. is affirmed in discharges through the respiratory parcel (Stevens et al. 2000). Artful intrusive parasitic contaminations (IFI) cause horribleness in the majority of the patients which are relocate beneficiary immunocompromised patients (Ho et al. 1983). It is truly challenging to analyze obtrusive parasitic contamination at beginning phases as its clinical elements are vague (Warnock et al. 1998). In any case, there are different strategies to analyze obtrusive aspergillosis (IA) particularly through mechanized tomography specifically known as (CT) examining however the treatment of intrusive aspergillosis is still truly challenging, and the death rate is 80-90% (Kim et al. 2001). There has consistently been an absence of procedures particularly culture methods in immunocompromised patients for early analysis of aspergillosis (Jones 1990). It was truly necessary to analyze these contagious diseases of IFI and for this reason, a new and speedy strategy for PCR is presented in which various tests are created to analyze and examine parasitic contaminations in the clinical examples as this PCR procedure has a high affectability for *Aspergillus* spp. (Morace et al. 1997). For this reason, MagNa unadulterated LC instrument for DNA extraction of *Aspergillus* spp. alongside continuous PCR light cyler framework which requires 6 hours for complete execution is utilized. Then, at that point, results are figured from tests taken from suspected patients with IFI and afterward contrasted and ordinarily gathered outcomes. half of patients experiencing leukemia got mortal because of absence of early analysis of *Aspergillus* spp. as indicated by norms of the European association of exploration and therapy of malignancy and mycosis concentrate on gathering of the public establishment of sensitivity and irresistible illness has permitted results examinations from various examinations and afterward PCR advancement and ongoing measure innovations to research and affirm the presence

of *Aspergillus* spp. in the respiratory discharge tests (Ramirez et al. 2009; Chong et al. 2015). The presence of *Aspergillus* spp. in the examples analyze aspergillosis at the last stages where the odds of mortality have been expanded. While it is extremely challenging to analyze and examine contagious diseases of *Aspergillus* spp. at beginning phases. Hence, treatment of contagious contamination is additionally truly challenging at that stage.

Materials and Methods:

Respiratory liquids of 100 patients in which 50 were male and 50 females between the age of 40 to 50 were gathered including Bronchoalveolar lavage, bronchial suction, sputa, pleural liquids, tracheal suction, and through the lung biopsy of basically sick patients which was affirmed by a worldwide board of trustees of specialists accessible at the hour of inspecting and checking (Denning et al. 2003; Schweer et al. 2014; Verweij et al. 2016). Patients were age somewhere in the range of 40 and 50 years. Tests were shipped off the research center from patients which were at high danger of contagious diseases and a few patients' outcomes were needed for affirmation of parasitic contaminations after and before treatment. Every example from every one of the patients was assessed through culture, PCR, and sequencing. Then, at that point, required grouping was placed into a data set NCBI to recognize *Aspergillus* spp. *Aspergillus* societies were developed at Sabouraud dextrose agar at 35 °C for 72 hours. Then, at that point, parasitic suspensions in saline were changed from 1x10⁶ to 5x10⁶ cells per ml⁻¹. Then, at that point, DNA was extricated. All the example liquid from all patients was centrifuged at 16000g for 10 minutes at 4 °C. Tests then, at that point, were handled with removed DNA through the Expert Unadulterated Yeast DNA filtration pack (Zhao et al. 2013). Preliminaries and hybridization tests were ready for *Aspergillus* spp. through strategy clarified by Loeffler et al. (2015) in which each PCR had negative control having water just without DNA layout while positive control had parasitic DNA format for each PCR for each example. PCR was utilized for the intensification of parasitic DNA. For intensification of ORF, Advertiser district, PCR amplicons DNA arrangement, these were dazed performed for all examples as the strategy recently utilized (Zhao et al. 2013; Zhao et al. 2016). For the enhancement of *Aspergillus* DNA, a light cycler framework was presented. This light cycler hot beginning PCR was acted in glass vessels with a light cycler quick beginning light cycler DNA ace hybridization test unit which is made explicit by makers. PCR ace blend was containing a quick beginning response combination with Taq. DNA polymerase, dNTPs, response cushion, 1.6 µl of 25 mmol l⁻¹ MgCl₂, 2µl of hybridization test, and 1.2 µl of every preliminary. PCR was then acted in 20µl volume in which there was 10µl DNA concentrate and 10µl of the expert blend at 95 °C for 10 minutes then, at that point, followed 50 patterns of 15 s at 95 °C, 10 s at 58 °C and 20 s at 72 °C with 20 °C/s temperature change rate (TTR). Then, at that point, PCR was trailed by softening temperature investigation of 95 °C for 10 s and 50 °C for 60 s (TTR 20 °C/s

each) and 75 °c for 0 s at TTR 0.1 °c/s for checking the PCR item explicitness (Ramires et al. 2009; White et al. 2015). The succession was placed into an information base and distinguished as *Aspergillus fumigatus* F-TGGACTATGCAGGGCACAAG/R-CCGCCAGATCACCCAGTATC, 510 bp, NCBI Reference grouping, NC-007198.1 and *Aspergillus niger* NCBI Reference arrangement, NT-166529.1 through NCBI. F-GGTAACCTCTCCCACCACC/R-CTCCGCGTCCTTCACTTTCT, 503 bp.

Information were investigated through a factual bundle for sociologies (SPSS) in which first ordinariness was checked. The information was ordinary and in this way information were looked at between sexual orientations (guys/females) in which the chances proportion was checked to screen either females are at significant danger of having illness or guys. Then, at that point, proportions of disease in both male and female was independently noted for the two kinds of irresistible growths either *Aspergillus fumigatus* or *Aspergillus niger*. Chances proportions for the two sorts of parasites and their danger factor were determined.

Results:

The results of the PCR showed the positive identity of the *Aspergillus fumigatus* in the samples in agarose gel electrophoresis with in 510bp. The gene specific regions were amplified at 510bp for the *Aspergillus fumigatus*, figure (1).

The results of the PCR showed the positive identity of the *Aspergillus niger* in the samples in agarose gel electrophoresis with in 503bp. The gene specific regions were amplified at 503bp for the *Aspergillus niger*, figure (2)




Fig. 1 Showing the bands of *Aspergillus fumigatus* through electrophoresis




Fig. 2 Indicating the bands of *Aspergillus niger* through electrophoresis

Discussion:

Around a sum of 100 examples were taken from respiratory plots of 50 male and 50 female patients between the age of 40 to 50, conceded in medical clinic ICU who was seriously sick for quite a while. As the early determination of aspergillosis was troublesome and couldn't analyze because of absence of strategies and indications of disease. So patients are determined to have aspergillosis at the late stage so later patients were likewise given steroids to adapt to the sickness and other contagious contaminations. The patients with an immunocompromised resistant framework were given steroids and later their commonness was observed. The patients were having *Aspergillus* spp. in liquid examples which affirmed and analyzed aspergillosis yet at a later stage through PCR.

Patients in ICU with the basic disease have obtrusive aspergillosis because of intravenous infusion of corticosteroids (Crean et al. 1992) and this treatment was allowed for multi week. However, in my review, the treatment was allowed for quite some time as the patients were basically sick and had COPD and respiratory disappointment also and were in ICU adequately delayed (Afessa et al. 2002) while patients which were not infused corticosteroid had no *Aspergillus* spp. in the examples. Treatment of neutropenia patients with fluconazole had the most noteworthy pace of confinement of *Aspergillus* spp. from patients (Meis et al. 1993). *Aspergillus* spp. show recuperation in respiratory emissions which shows the colonization of *Aspergillus* spp. without a trace of pneumonia signs. Then, at that point, a few patients were additionally treated with antifungal and later these patients show antifungal utilized alongside *Aspergillus* spp. colonization in the examples from the respiratory parcel regardless of bacterial colonization in other patient examples. Histopathological discoveries through post-mortems affirmed clinical determination of *Aspergillus* spp. also, these discoveries show similar outcomes as recently introduced through the quantitative upsides of *Aspergillus* spp. present in respiratory examples of COPD patients taking corticosteroids for a more extended span of treatment (Dimopoulos et al. 2003; Van et al. 2015). While it digresses from past investigations of

Petri et al. (1997) that 435 patients tests with no neutropenic were dissected and there were just 4% examples that show contagious colonization with *Aspergillus* spp. while others show no conclusion positive for intrusive Aspergillosis. 60% of patients were additionally determined to have aspergillosis which was not getting antifungal treatment, and this was all because of absence of generally solid and real analytic instruments and strategies (Groll et al. 1996). This strategy for *Aspergillus* spp. finding is likewise not real or solid for analysis of aspergillosis through respiratory emissions of patients who were suspected for aspergillosis. While in another review, patients were analyzed positive for *Aspergillus* spp. however, they were not associated with obtrusive aspergillosis even in non-immunosuppressed patients (Victor et al. 1986). While patients with diabetes mellitus, hunger, an aspiratory issue, or patients which were being treated with corticosteroids were at high danger of obtrusive aspergillosis having *Aspergillus* spp. present in respiratory discharges (Amazing et al. 2001). It was taken as the patients with immunocompromised conditions just can have intrusive aspergillosis (Chen et al. 2001) yet some clinical reports likewise show positive outcomes for intrusive aspergillosis diagnosing of *Aspergillus* spp. which already have no signs or likelihood hazard finishes paperwork for aspergillosis (Peterson et al. 2000). Furthermore, intense local area gained pneumonia is likewise analyzed because of *Aspergillus* spp. in even immunocompetent people (Clancy et al. 1998).

Their most elevated danger of aspergillosis in patients experiencing neutropenia as neutrophils and monocyte is the first line of guard against *Aspergillus* spp. which is either *Aspergillus fumigatus* or *Aspergillus niger* (Denning 1998). And furthermore the Lymphocyte obtained resistance assumes an indispensable part in safeguard against *Aspergillus* spp. accordingly (Latge 1998). The patients which are conceded to emergency clinics for quite a while need to confront various variables and because of affliction to bed for quite a while, their safe framework gets poor and macrophages got deactivated and adjusting the capacities and reactions against microorganisms (Lederer et al. 1998). Different variables impact insusceptible reactions. Hyperglycemia impacts the working of fringe neutrophils (Kwoun et al. 1997). This is likewise checked from past examinations that the utilization of corticosteroids smothers the typical working of neutrophils against *Aspergillus* spp. accordingly (Roilides et al. 1993). There is equivocalness in observing the connection between *Aspergillus* contaminations concerning affirmation in ICU and their diminishing in resistance because of various variables like multi-organ disappointment, immunoparalysis, and mitigating reaction disorder (Hartemink et al. 2003).

As the infection isn't analyzed at beginning phases because of a lack of procedures. At the point when it is analyzed, there has a high spread of illness and at that stage, it is difficult to treat totally and adequately. So there is a recorded high death rate for seriously sick patients experiencing

obtrusive aspergillosis (Meersseman et al. 2004; Vermeulen et al. 2013). There are diverse incidental factors too which affect the sickness reconnaissance so mortality because of intrusive aspergillosis comes to 18.9% when superfluous factors were corrected (Vandewoude et al. 2004). There is no determination of aspergillosis at beginning phases and just it is analyzed at late stages without beginning any treatment whatsoever stages. This analysis disappointment and late treatment is the fundamental driver of this high mortality because of aspergillosis. Amphotericin B deoxycholate was recently utilized generally for against parasitic medicines. While later amphotericin B lipid definition was begun eliminating amphotericin b deoxycholate as it effectsly affected patients experiencing extreme sickness and taking clinical therapy (Wingard et al. 1998). As the amphotericin b lipids definition is superior to amphotericin b deoxycholate yet it isn't shown for treatment (Stevens et al. 2000). This amphotericin b lipid detailing is better for basically sick patients with intrusive aspergillosis having better resilience (Gottfredsson and Wonderful 1999). Be that as it may, presently there is the accessibility of the most exceptional enemy of parasitic specialists as a treatment against *Aspergillus* spp. There are utilized these days voriconazole for the treatment of obtrusive aspergillosis which is best against *Aspergillus* spp. than introductory standard methodology recently utilized as amphotericin b deoxycholate and amphotericin d lipids definition (Herbrecht et al. 2002). Caspofungin is likewise best against obtrusive aspergillosis than standard methodologies recently utilized as treated with amphotericin b deoxycholate and amphotericin b lipids definition (Maertens et al. 2004). A new report uncovers significance with respect to the meaning of *Aspergillus* spp. confinement through respiratory discharges in fundamentally sick patients.

References:

Afessa, B., Morales, I. J., Scanlon, P. D., & Peters, S. G. (2002). Prognostic factors, clinical course, and hospital outcome of patients with chronic obstructive pulmonary disease admitted to an intensive care unit for acute respiratory failure. *Critical care medicine*, 30(7), 1610-1615. doi: 10.1097/00003246-200207000-00035.

Ascioglu, S., Rex, J. H., De Pauw, B., Bennett, J. E., Bille, J., Crokaert, F., & Stevens, D. A. (2003). Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. *Проблемы медицинской микологии*, 5(1). doi: 10.1086/323335. Epub 2001 Nov 26.

Chen, K. Y., Ko, S. C., Hsueh, P. R., Luh, K. T., & Yang, P. C. (2001). Pulmonary fungal infection: emphasis on microbiological spectra, patient outcome, and prognostic factors. *Chest*, 120(1), 177-184. doi: 10.1378/chest.120.1.177.

Clancy, C. J., & Nguyen, M. H. (1998). Acute community-acquired pneumonia due to *Aspergillus* in presumably immunocompetent hosts: clues for recognition of a rare but fatal disease. *Chest*, 114(2), 629-634. doi: 10.1378/chest.114.2.629.

CREAN, J. M., NIEDERMAN, M. S., FEIN, A. M., & FEINSILVER, S. H. (1992). Rapidly progressive respiratory failure due to *Aspergillus* pneumonia: a complication of short-term corticosteroid therapy. *Critical care medicine*, 20(1), 148-150. doi: 10.1097/00003246-199201000-00028.

Denning, D. W. (1998). Invasive aspergillosis. *Clinical infectious diseases*, 781-803. doi: 10.1086/513943.

Denning, D. W. (2000). *Aspergillus* species. <https://doi.org/10.1128/AAC.44.2.441-443.2000>

Dimopoulos, G., Piagnerelli, M., Berré, J., Eddafali, B., Salmon, I., & Vincent, J. L. (2003). Disseminated aspergillosis in intensive care unit patients: an autopsy study. *Journal of chemotherapy*, 15(1), 71-75. doi: 10.1179/joc.2003.15.1.71.

Garnacho-Montero, J., Amaya-Villar, R., Ortiz-Leyba, C., León, C., Álvarez-Lerma, F., Nolla-Salas, J., & Barcenilla, F. (2005). Isolation of *Aspergillus* spp. from the respiratory tract in critically ill patients: risk factors, clinical presentation and outcome. *Critical Care*, 9(3), 1-9. <https://dx.doi.org/10.1186%2Fcc3488>

Gottfredsson, M., & Perfect, J. R. (1999). Use of antifungal agents in the intensive care unit. *Current Opinion in Critical Care*, 5(5), 381-390.

Groll, A. H., Shah, P. M., Mentzel, C., Schneider, M., Just-Nuebling, G., & Huebner, K. (1996). Trends in the postmortem epidemiology of invasive fungal infections at a university hospital. *Journal of infection*, 33(1), 23-32. doi: 10.1016/s0163-4453(96)92700-0.

Hartemink, K. J., Paul, M. A., Spijkstra, J. J., Girbes, A. R., & Polderman, K. H. (2003). Immunoparalysis as a cause for invasive aspergillosis? *Intensive care medicine*, 29(11), 2068-2071. doi: 10.1007/s00134-003-1778-z. Epub 2003 May 24.

Herbrecht, R., Denning, D. W., Patterson, T. F., Bennett, J. E., Greene, R. E., Oestmann, J. W., ... & De Pauw, B. (2002). Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. *New England Journal of Medicine*, 347(6), 408-415. doi: 10.1056/NEJMoa020191.

Ho, M. A. J. T. T. H., Wajszczuk, C. P., & Hardy, A. (1983, January). Infections in kidney, heart, and liver transplant recipients on cyclosporine. In *Transplantation Proceedings* (Vol. 15, No. 4 SUPP, pp. 2768-2772). University of Pittsburgh. doi: 10.1097/00007890-198309000-00007.

Humphreys, H., Johnson, E. M., Warnock, D. W., Willatts, S. M., Winter, R. J., & Speller, D. C. E. (1991). An outbreak of aspergillosis in a general ITU. *Journal of Hospital Infection*, 18(3), 167-177. doi: 10.1016/0195-6701(91)90141-t.

Jones, J. M. (1990). Laboratory diagnosis of invasive candidiasis. *Clinical Microbiology Reviews*, 3(1), 32-45. <https://dx.doi.org/10.1128%2Fcmr.3.1.32>

Kim, M. J., Lee, K. S., Kim, J., Jung, K. J., Lee, H. G., & Kim, T. S. (2001). Crescent sign in invasive pulmonary aspergillosis: frequency and related CT and clinical factors. *Journal of computer assisted tomography*, 25(2), 305-310. doi: 10.1097/00004728-200103000-00027.

Klingspor, L., & Jalal, S. (2006). Molecular detection and identification of *Candida* and *Aspergillus* spp. from clinical samples using real-time PCR. *Clinical microbiology and infection*, 12(8), 745-753. <https://doi.org/10.1111/j.1469-0691.2006.01498.x>

Kwoun, M. O., Ling, P. R., Lydon, E., Imrich, A., Qu, Z., Palombo, J., & Bistrrian, B. R. (1997). Immunologic effects of acute hyperglycemia in nondiabetic rats. *Journal of Parenteral and Enteral Nutrition*, 21(2), 91-95. DOI: 10.1177/014860719702100291

Latgé, J. P. (1999). *Aspergillus fumigatus* and aspergillosis. *Clinical microbiology reviews*, 12(2), 310-350. doi: 10.1128/CMR.12.2.310.

Lederer, J. A., Rodrick, M. L., & Mannick, J. A. (1999). The effects of injury on the adaptive immune response. *Shock (Augusta, Ga.)*, 11(3), 153-159. doi: 10.1097/00024382-199903000-00001.

Maertens, J., Raad, I., Petrikos, G., Boogaerts, M., Selleslag, D., Petersen, F. B., & Caspofungin Salvage Aspergillosis Study Group. (2004). Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. *Clinical Infectious Diseases*, 39(11), 1563-1571. doi: 10.1086/423381. Epub 2004 Nov 9.

Meersseman, W., Vandecasteele, S. J., Wilmer, A., Verbeken, E., Peetermans, W. E., & Van Wijngaerden, E. (2004). Invasive aspergillosis in critically ill patients without malignancy. *American journal of respiratory and critical care medicine*, 170(6), 621-625. doi: 10.1164/rccm.200401-093OC. Epub 2004 Jun 30.

Meis, J. F., Donnelly, J. P., Hoogkamp-Korstanje, J. A., & De Pauw, B. E. (1993). *Aspergillus fumigatus* pneumonia in neutropenic patients during therapy with fluconazole for infection due to *Candida* species. *Clinical infectious diseases*, 16(5), 734-735. doi: 10.1093/clind/16.5.734.

Morace, G., Sanguinetti, M., Posteraro, B., Lo Cascio, G., & Fadda, G. (1997). Identification of various medically important *Candida* species in clinical specimens by PCR-restriction enzyme

analysis. *Journal of Clinical Microbiology*, 35(3), 667-672. <https://www.ncbi.nlm.nih.gov/pubmed/9041409>

Paterson, T. F., Kirkpatrick, W. R., White, M., Hiemenz, J. W., Wingard, J. R., DuPont, B., ... & Graybill, J. R. (2000). Invasive aspergillosis: Disease spectrum, treatment practices, and outcomes. *Medicine (Baltimore)*, 79, 250-260. doi: 10.1097/00005792-200007000-00006.

Perfect, J., Cox, G. M., Lee, J. Y., Kauffman, C. A., De Repentigny, L., Chapman, S. W., ... & Stevens, D. A. (2001). The impact of culture isolation of *Aspergillus* species: a hospital-based survey of aspergillosis. *Clinical Infectious Diseases*, 33(11), 1824-1833. doi: 10.1086/323900. Epub 2001 Oct 22.

Petri, M. G., König, J., Moecke, H. P., Gramm, H. J., Barkow, H., Kujath, P., ... & Lode, H. (1997). Epidemiology of invasive mycosis in ICU patients: a prospective multicenter study in 435 non-neutropenic patients. *Intensive care medicine*, 23(3), 317-325. doi: 10.1007/s001340050334.

Roilides, E., Uhlig, K., Venzon, D., Pizzo, P. A., & Walsh, T. J. (1993). Prevention of corticosteroid-induced suppression of human polymorphonuclear leukocyte-induced damage of *Aspergillus fumigatus* hyphae by granulocyte colony-stimulating factor and gamma interferon. *Infection and Immunity*, 61(11), 4870-4877. doi: 10.1128/iai.61.11.4870-4877.1993.

Stevens, D. A., Kan, V. L., Judson, M. A., Morrison, V. A., Dummer, S., Denning, D. W., ... & Pankey, G. A. (2000). Practice guidelines for diseases caused by *Aspergillus*. *Clinical Infectious Diseases*, 696-709. doi: 10.1086/313756. Epub 2000 Apr 20.

Vandewoude, K. H., Blot, S. I., Benoit, D. O. M. I. N. I. Q. U. E., Colardyn, F., & Vogelaers, D. (2004). Invasive aspergillosis in critically ill patients: attributable mortality and excesses in length of ICU stay and ventilator dependence. *Journal of Hospital Infection*, 56(4), 269-276. <https://doi.org/10.1016/j.jhin.2004.01.006>

Victor, L. Y., Muder, R. R., & Poorsattar, A. (1986). Significance of isolation of *Aspergillus* from the respiratory tract in diagnosis of invasive pulmonary aspergillosis. Results from a three-year prospective study. *The American journal of medicine*, 81(2), 249-254. doi: 10.1016/0002-9343(86)90259-7.

Warnock, D. W. (1998). Fungal infections in neutropenia: current problems and chemotherapeutic control. *The Journal of antimicrobial chemotherapy*, 41(suppl_4), 95-105. https://doi.org/10.1093/jac/41.suppl_4.95

Wingard, J. R., Kubilis, P., Lee, L., Yee, G., White, M., Louise, W., & Lister, J. (1999). Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis. *Clinical infectious diseases*, 29(6), 1402-1407. doi: 10.1086/313498.

Zhao, Y., Garnaud, C., Brenier-Pinchart, M. P., Thiébaud-Bertrand, A., Saint-Raymond, C., Camara, B., & Perlin, D. S. (2016). Direct molecular diagnosis of aspergillosis and CYP51A profiling from respiratory samples of French patients. *Frontiers in microbiology*, 7, 1164. <https://doi.org/10.3389/fmicb.2016.01164>

Zhao, Y., Stensvold, C. R., Perlin, D. S., and Arendrup, M. C. (2013). Azole resistance in *Aspergillus fumigatus* from bronchoalveolar lavage fluid samples of patients with chronic diseases. *J. Antimicrob. Chemother.* 68, 1497–1504. doi: 10.1093/jac/dkt071. doi: 10.1093/jac/dkt071. Epub 2013 Mar 5.

Verweij PE, Zhang J, Debets AJM, Meis JF, van de Veerdonk FL, Schoustra SE, Zwaan BJ, Melchers W. 2016. In-host adaptation and acquired triazole resistance in *Aspergillus fumigatus*: a dilemma for clinical management. *Lancet Infect Dis* 16:e251–e260. [10.1016/S1473-3099\(16\)30138-4](https://doi.org/10.1016/S1473-3099(16)30138-4). [PubMed](#)

Chong GL, van de Sande WW, Dingemans GJ, Gaajetaan GR, Vonk AG, Hayette MP, van Tegelen DW, Simons GF, and Rijnders BJ. 2015. Validation of a new *Aspergillus* real-time PCR assay for direct detection of *Aspergillus* and azole resistance of *Aspergillus fumigatus* on bronchoalveolar lavage fluid. *J Clin Microbiol* 53:868–874. [10.1128/JCM.03216-14](https://doi.org/10.1128/JCM.03216-14). [Crossref](#). [PubMed](#).

White PL, Posso RB, and Barnes RA. 2015. Analytical and clinical evaluation of the PathoNosticsAsperGenius assay for detection of invasive aspergillosis and resistance to azole antifungal drugs during testing of serum samples. *J Clin Microbiol* 53:2115–2121. [10.1128/JCM.00667-15](https://doi.org/10.1128/JCM.00667-15). [Crossref](#). [PubMed](#).

Van der Linden JW, Arendrup MC, Warris A, Lagrou K, Pelloux H, Hauser PM, Chryssanthou E, Mellado E, Kidd SE, Tortorano AM, Dannaoui E, Gaustad P, Baddley JW, Uekotter A, Lass-Flörl C, Klimko N, Moore CB, Denning DW, Pasqualotto AC, Kibbler C, Arikan-Akdagli S, Andes D, Meletiadis J, Naumiuk L, Nucci M, Melchers WJ, and Verweij PE. 2015. Prospective multicenter international surveillance of azole resistance in *Aspergillus fumigatus*. *Emerg Infect Dis* 21:1041–1044. [10.3201/eid2106.140717](https://doi.org/10.3201/eid2106.140717). [Crossref](#). [PubMed](#).

Vermeulen E, Lagrou K, and Verweij PE. 2013. Azole resistance in *Aspergillus fumigatus*: a growing public health concern. *Curr Opin Infect Dis* 26:493–500. [10.1097/QCO.0000000000000005](https://doi.org/10.1097/QCO.0000000000000005). [Crossref](#). [PubMed](#).